In conclusion, reboxetine seems to be an antidepressant with negligible interference with the pharmacokinetics of other drugs thus fewer drug-drug interactions are expected. The effects of antidepressants on psychomotor function with particular reference to reboxetine. This review assesses the relative efficacy and side-effect profile of the currently available treatment options for major depression and the new selective noradrenergic agent, reboxetine. In comparison, the newer noradrenergic agents such as reboxetine have demonstrated significant improvements in the incidence and severity of effects on psychomotor function. Such a lack of side-effects makes agents like reboxetine most useful for the treatment of depression in ambulant patients performing their usual activities of daily living.
Depression is thought to result from a dysfunction in the noradrenergic or serotonergic systems.
The noradrenergic system appears to be associated with increased drive, whereas the serotonergic system relates more to changes in mood and it is possible that the different symptoms of depression may benefit from drugs acting mainly on one or other of the neurotransmitter systems. This suggests that the two classes of drugs owe their activity to functional changes in different neurotransmitter systems. NARIs have a role in the treatment of depression, either alone or as adjunctive therapy. Single against repeated oral doses and lack of enzymatic alterations. Pellizzoni C, Poggesi I, Jorgensen NP, Edwards DM, Paus E, Strolin Benedetti M Pharmacia, Pharmacokinetics and Metabolism, Milan, Italy.